Lipella Pharmaceuticals Inc. (LIPO)
NASDAQ: LIPO · IEX Real-Time Price · USD
0.457
-0.010 (-2.12%)
At close: Jul 19, 2024, 4:00 PM
0.360
-0.097 (-21.24%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.
The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).
Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Lipella Pharmaceuticals Inc.
| Country | United States |
| Founded | 2005 |
| IPO Date | Dec 20, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Dr. Jonathan Kaufman M.B.A., Ph.D. |
Contact Details
Address: 400 N Lexington St, Ste Ll103 Pittsburgh, Pennsylvania 15208 United States | |
| Phone | 412-901-0315 |
| Website | lipella.com |
Stock Details
| Ticker Symbol | LIPO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.75 |
| CIK Code | 0001347242 |
| CUSIP Number | 53630L100 |
| ISIN Number | US53630L1008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jonathan Kaufman M.B.A., Ph.D. | Co-Founder, Chairman, Chief Executive Officer, President, Secretary and Treasurer |
| Dr. Michael B. Chancellor M.D. | Co-Founder, Chief Medical Officer and Director |
| Douglas Johnston CPA | Chief Financial Officer |
| Michele Gruber | Director of Operations |
| Katie Johnston | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2024 | 10-Q | Quarterly Report |
| May 6, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 19, 2024 | 8-K | Current Report |
| Apr 12, 2024 | 8-K | Current Report |
| Mar 19, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 15, 2024 | 8-K | Current Report |
| Mar 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 15, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 6, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |